Last quarter (Q4 2023), BioCryst's total revenue was $93.40M, an increase of 17.42% from the same quarter last year. In Q4, BioCryst's net income was $-61.73M. See BioCryst’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 262.63M	$ 331.41M	$ 270.83M	$ 157.23M	$ 17.81M	$ 48.84M
Cost of Revenue	$ 4.49M	$ 4.48M	$ 6.41M	$ 7.26M	$ 1.68M	$ 4.10M
Gross Profit	$ 258.20M	$ 326.93M	$ 264.42M	$ 149.97M	$ 16.14M	$ 44.73M
Operating Expense	$ 430.46M	$ 430.46M	$ 412.67M	$ 327.63M	$ 190.89M	$ 144.19M
Operating Income	$ -172.38M	$ -103.71M	$ -148.44M	$ -177.66M	$ -174.76M	$ -99.45M
Net Non Operating Interest Income Expense	$ -104.86M	$ -108.24M	$ -99.09M	$ -59.29M	$ -5.08M	$ -9.96M
Other Income Expense	$ -39.53M	$ 29.02M	-	$ -55.84M	$ -2.98M	$ 517.00K
Pretax Income	$ -226.23M	$ -226.23M	$ -244.38M	$ -181.81M	$ -182.81M	$ -108.90M
Tax Provision	$ 310.00K	$ 310.00K	$ 2.73M	$ 2.25M	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -230.65M	$ -226.54M	$ -251.87M	$ -184.06M	$ -182.81M	$ -108.90M
Basic EPS	-	-	-	-	$ -1.09	$ -0.94
Diluted EPS	-	-	-	-	$ -1.09	$ -0.94
Basic Average Shares	-	-	-	-	$ 167.27M	$ 115.60M
Diluted Average Shares	-	-	-	-	$ 167.27M	$ 115.60M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 434.95M	$ 434.94M	$ 419.08M	$ 334.89M	$ 192.57M	$ 148.29M
Net Income From Continuing And Discontinued Operation	$ -226.54M	$ -226.54M	$ -247.12M	$ -184.06M	$ -182.81M	$ -108.90M
Normalized Income	$ -87.22M	-	-	-	$ -179.84M	$ -109.41M
Interest Expense	-	-	-	-	$ 14.50M	$ 11.89M
EBIT	$ -164.29M	$ -117.99M	$ -145.29M	$ -122.52M	$ -168.31M	$ -97.00M
EBITDA	$ -102.16M	$ -126.60M	$ -46.71M	$ -67.54M	$ -167.56M	$ -96.28M

Currency in USD

BioCryst Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing